197 related articles for article (PubMed ID: 28397975)
1. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.
Keller A; Wingelhofer B; Peter B; Bauer K; Berger D; Gamperl S; Reifinger M; Cerny-Reiterer S; Moriggl R; Willmann M; Valent P; Hadzijusufovic E
Vet Comp Oncol; 2018 Mar; 16(1):55-68. PubMed ID: 28397975
[TBL] [Abstract][Full Text] [Related]
2. Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Gamperl S; Stefanzl G; Peter B; Smiljkovic D; Bauer K; Willmann M; Valent P; Hadzijusufovic E
Vet Comp Oncol; 2019 Dec; 17(4):553-561. PubMed ID: 31286638
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
[TBL] [Abstract][Full Text] [Related]
5. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells.
Lasho T; Tefferi A; Pardanani A
Leukemia; 2010 Jul; 24(7):1378-80. PubMed ID: 20485374
[No Abstract] [Full Text] [Related]
7. Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Barrio S; Gallardo M; Arenas A; Ayala R; Rapado I; Rueda D; Jiménez-Ubieto A; Albizua E; Burgaleta C; Gilsanz F; Martinez-Lopez J
Br J Haematol; 2013 Jun; 161(5):667-676. PubMed ID: 23560534
[TBL] [Abstract][Full Text] [Related]
8. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
Gallipoli P; Cook A; Rhodes S; Hopcroft L; Wheadon H; Whetton AD; Jørgensen HG; Bhatia R; Holyoake TL
Blood; 2014 Aug; 124(9):1492-501. PubMed ID: 24957147
[TBL] [Abstract][Full Text] [Related]
9. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
Hadzijusufovic E; Rebuzzi L; Gleixner KV; Ferenc V; Peter B; Kondo R; Gruze A; Kneidinger M; Krauth MT; Mayerhofer M; Samorapoompichit P; Greish K; Iyer AK; Pickl WF; Maeda H; Willmann M; Valent P
Exp Hematol; 2008 Nov; 36(11):1461-70. PubMed ID: 18723263
[TBL] [Abstract][Full Text] [Related]
10. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Okabe S; Tauchi T; Katagiri S; Tanaka Y; Ohyashiki K
J Hematol Oncol; 2014 Apr; 7():37. PubMed ID: 24775308
[TBL] [Abstract][Full Text] [Related]
11. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
Rebuzzi L; Willmann M; Sonneck K; Gleixner KV; Florian S; Kondo R; Mayerhofer M; Vales A; Gruze A; Pickl WF; Thalhammer JG; Valent P
Vet Immunol Immunopathol; 2007 Feb; 115(3-4):320-33. PubMed ID: 17196258
[TBL] [Abstract][Full Text] [Related]
12. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
[TBL] [Abstract][Full Text] [Related]
13. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
[TBL] [Abstract][Full Text] [Related]
15. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Elders RC; Baines SJ; Catchpole B
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line.
Guvenir Celik E; Eroglu O
Mol Biol Rep; 2023 Jan; 50(1):319-329. PubMed ID: 36331743
[TBL] [Abstract][Full Text] [Related]
18. NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.
Hadzijusufovic E; Peter B; Herrmann H; Rülicke T; Cerny-Reiterer S; Schuch K; Kenner L; Thaiwong T; Yuzbasiyan-Gurkan V; Pickl WF; Willmann M; Valent P
Allergy; 2012 Jul; 67(7):858-68. PubMed ID: 22583069
[TBL] [Abstract][Full Text] [Related]
19. JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.
Lu Z; Hong CC; Jark PC; Assumpção ALFV; Bollig N; Kong G; Pan X
J Vet Intern Med; 2017 Nov; 31(6):1804-1815. PubMed ID: 28960447
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
Tong H; Ren Y; Zhang F; Jin J
Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
